Clinical-stage leverage Capitalize on ST-001's ongoing Phase 1a trial for T-cell NHL with upcoming data presentations and a second IND clearance for SCLC to cultivate partnerships and milestone-driven collaborations with biotech and specialty pharma seeking oncology assets.

Strategic fundraising Utilize the recent funding rounds and growing investor interest to create co-development and strategic investment opportunities, offering partners shared risk and accelerated development timelines around ST-001 and related nanomedicine platforms.

Nano delivery edge Position ST-001’s nanoparticle delivery system as a differentiator for partners aiming to improve bioavailability and targeted delivery across multiple solid and hematologic cancers, enabling combination therapies with existing regimens.

Clinical outreach Leverage recent conference presence and leadership additions to establish key opinion leader (KOL) engagements, site partnerships, and early-access discussions with cancer centers and contract research organizations seeking innovative oncology assets.

Manufacturing readiness Highlight scalable nanomanufacturing capabilities to potential CDMOs and pharma manufacturers interested in fast-tracking from lab to clinic, offering scalable production solutions and potential manufacturing collaborations.